Despite many therapeutic options available only one-third of hypertensive patients achieve target Blood pressure (BP). The present study was undertaken to evaluate the efficacy and safety of triple drug, fixed dose combination of Telmisartan 40 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5mg, in the management of hypertensive patients with or without co-morbidities. A total of 60 patients were enrolled on the basis of mean seated cuff systolic blood pressure >160 mmHg and diastolic blood pressure >100 mmHg in this post-marketing surveillance (PMS) study. Patients were prescribed triple drug fixed dose combination for 120 days. In all groups (diabetic hypertensive, Dyslipidemic hypertensive and hypertension without any complication) there was statistically significant decrease (p<0.0001) in systolic blood pressure (SBP) from the baseline to 30th, 60th and 120th days of the treatment. Diastolic BP (DBP) was significantly decreased (p<0.0001) from the baseline just after 15th day of the treatment and on subsequent days of observation. 50% of diabetic hypertensive patients and 78.5% of hypertensive patients with dyslipidaemia achieved the Joint national committee VII (JNC VII) recommended goal (130/80mm Hg) at the end of study period of 120 days. Similarly in patients with hypertension without complication, 81.3% achieved the JNC VII recommended goal (140/90mm Hg) at the end of the study period. Triple drug fixed dose combination therapy of Telmisartan, Amlodipine and hydrochlorothiazide has been shown to be an effective, safe and convenient treatment strategy in controlling the blood pressure and achieving the desired blood pressure goal.